Advertisement

Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Purpose

      The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial.

      Patients and Methods

      Patients received every-3-week therapy (n = 43) consisting of a 200 mg/m2 dose of paclitaxel/carboplatin area under the curve (AUC) of 6 mg/mL per minute and trastuzumab (an initial 8 mg/kg dose and subsequent 6 mg/kg doses) administered every 21 days for 8 cycles or weekly therapy (n = 48) consisting of an 80-mg/m2 dose of paclitaxel/carboplatin AUC of 2 mg/mL per minute for 3 of 4 weeks, with weekly trastuzumab (an initial 4-mg/kg dose and subsequent 2-mg/kg doses) administered every 4 weeks for 6 cycles. Trastuzumab was continued until disease progression or unacceptable toxicity. HER2 status was confirmed by a central laboratory review.

      Results

      The overall response rate (ORR) with every-3-week therapy was 65% (90% confidence interval [CI], 51%–77%), with a median time to disease progression of 9.9 months and median overall survival (OS) time of 2.3 years. The ORR with weekly therapy was 81% (90% CI, 70%–90%), with a median time to disease progression of 13.8 months and a median OS time of 3.2 years. Hematologic and nonhematologic toxicities occurred significantly less frequently with weekly therapy versus every-3-week therapy: grade 3/4 neutropenia (52% vs. 88%); grade 3 thrombocytopenia (4% vs. 30%); and grade 3 neurosensory toxicity (2% vs. 19%), respectively.

      Conclusions

      Every-3-week and weekly regimens of paclitaxel/carboplatin/trastuzumab are highly active in women with HER2-overexpressing MBC. However, fewer patients developed severe neutropenia, leukopenia, or thrombocytopenia with the weekly schedule.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pegram MD
        • Pienkowski T
        • Northfelt DW
        • et al.
        Results of two openlabel, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
        J Natl Cancer Inst. 2004; 96: 759-769
        • Burris III, H
        • Yardley D
        • Jones S
        • et al.
        Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
        J Clin Oncol. 2004; 22: 1621-1629
        • Robert NJ
        • Leyland-Jones B
        • Asmar L
        • et al.
        Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients wtih HER-2/neu positive advanced breast cancer.
        Breast Cancer Res Treat. 2002; 76 (Abstract #35).: S37
        • Calvert AH
        • Newell DR
        • Gumbrell LA
        • et al.
        Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
        J Clin Oncol. 1989; 7: 1748-1756
        • Perez EA
        • Hillman DW
        • Stella PJ
        • et al.
        A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.
        Cancer. 2000; 88: 124-131
        • Fountzilas G
        • Dimopoulos AM
        • Papadimitriou C
        • et al.
        First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.
        Ann Oncol. 1998; 9: 1031-1034
        • Fountzilas G
        • Athanassiadis A
        • Kalogera-Fountzila A
        • et al.
        Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group.
        Eur J Cancer. 1997; 33: 1893-1895
        • Loesch D
        • Robert N
        • Asmar L
        • et al.
        Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer.
        J Clin Oncol. 2002; 20: 3857-3864
        • Slamon DJ
        • Clark GM
        • Wong SG
        • et al.
        Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
        Science. 1987; 235: 177-182
        • Slamon DJ
        • Godolphin W
        • Jones LA
        • et al.
        Studies of the HER-2/neu protooncogene in human breast and ovarian cancer.
        Science. 1989; 244: 707-712
        • Ravdin PM
        • Chamness GC
        The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers–a review.
        Gene. 1995; 159: 19-27
        • Slamon DJ
        • Leyland-Jones B
        • Shak S
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Seidman A
        • Hudis C
        • Pierri MK
        • et al.
        Cardiac dysfunction in the trastuzumab clinical trials experience.
        J Clin Oncol. 2002; 20: 1215-1221
        • Martin M
        Platinum compounds in the treatment of advanced breast cancer.
        Clin Breast Cancer. 2001; 2: 190-208
        • Pegram M
        • Hsu S
        • Lewis G
        • et al.
        Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
        Oncogene. 1999; 18: 2241-2251
        • Pegram MD
        • Lopez A
        • Konecny G
        • et al.
        Trastuzumab and chemotherapeutics: drug interactions and synergies.
        Semin Oncol. 2000; 27: 21-25
        • Konecny G
        • Pegram MD
        • Beryt M
        • et al.
        Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cell with HER-2 neu overexpression.
        Br Cancer Res Treat. 1999; 57 (Abstract #114).: 114
        • Pietras RJ
        • Fendly BM
        • Chazin VR
        • et al.
        Antibody to HER-2/neu receptor blocks DNA repair after cisplatin human breast and ovarian cancer cells.
        Oncogene. 1994; 9: 1829-1838
        • Pietras RJ
        • Pegram MD
        • Finn RS
        • et al.
        Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
        Oncogene. 1998; 17: 2235-2249
        • Pegram M
        Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185-HER2/neu monoclonal antibody plus cisplatin in patients with Her2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
        J Clin Oncol. 1998; 16: 2659-2671
        • Cockcroft DW
        • Gault MH
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Kaplan E
        • Meier P
        Nonparametric estimation from incomplete observation.
        J Am Stat Assoc. 1958; 53: 456-481
        • Mass RD
        • Sanders C
        • Charlene K
        • et al.
        The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials.
        Proc Am Soc Clin Oncol. 2000; 19 (Abstract #291).: 75a
        • Leyland-Jones B
        • Gelmon K
        • Ayoub JP
        • et al.
        Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
        J Clin Oncol. 2003; 21: 3965-3971
        • Miles D
        • von Minckwitz G
        • Seidman AD
        Combination versus sequential single-agent therapy in metastatic breast cancer.
        Oncologist. 2002; 7: 13-19
        • Robert NJ
        • Leyland-Jones B
        • Asmar L
        • et al.
        Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: an update including survival.
        Proc Am Soc Clin Oncol. 2004; 22 (Abstract #573).: 14s
        • Fountzilas G
        • Tsavdaridis D
        • Kalogera-Fountzila A
        • et al.
        Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.
        Ann Oncol. 2001; 12: 1545-1551
        • Seidman AD
        • Fornier MN
        • Esteva FJ
        • et al.
        Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
        J Clin Oncol. 2001; 19: 2587-2595